Charting a Course to Value Assessment 2.0
IVI envisions a new approach to value assessment that is patient-centered, transparent, and adaptable to local contexts. We pursue that vision by:
Nearly unprecedented consensus has emerged over the need to align reimbursement and utilization with value… [but] we cannot reward value until we properly measure it.
The Open-Source Value Platform
Research Driving Progress
Research is the first ingredient in developing improved approaches to estimating value in healthcare. IVI’s research projects support the development of Open-Source Value Platform models providing insights into the patient experience and filling gaps in existing methods – and as IVI receives feedback on its work, our research plans continue to evolve.
Quantifying the Patient Experience: Developing Patient-Centered QALYs in Cancer (Ongoing)
Accurately capturing the experienced benefits and costs to patients is one of the most important challenges in value assessment – and it is crucial to understanding value. As a step toward developing improved measures that capture the diverse treatment experiences of patients, IVI is developing QALY measures tailored specifically to patients in treatment for a single disease: non-small cell lung cancer (NSCLC).
Patient Perspectives on Value in the Treatment of Non-Small Cell Lung Cancer
Understanding what determines value from the patient perspective is vital to healthcare decision-making and the delivery of high-quality clinical care. IVI conducted qualitative research to better understand how patients with non-small cell lung cancer (NSCLC) prioritize various treatment attributes, such as health states, side effects, and mode of administration. The findings from this research, outlined in the IVI report, are informing related research and model development at IVI by gaining a better understanding of the patient’s experience with lung cancer treatment.
Expanding Cost-Effectiveness Analysis (CEA) to All of Health Care: Comparisons Between CEAs on Pharmaceuticals and Medical/Surgical Procedures
Cost-effectiveness analysis has been applied extensively for pharmaceuticals, but less so for medical and surgical goods and services, we evaluate similarities and differences between characteristics of pharmaceutical CEA studies and CEA studies of medical or surgical procedures, and examine potential policy solutions to achieve a more balanced mix of CEAs across interventions and ultimately help us better diagnose and treat patients.
Patient Insights on Value in Rheumatoid Arthritis
IVI worked with focus groups to explore patient’s perspectives on care for rheumatoid arthritis (RA) and learn how RA patients deliberate their treatment options. The specific objectives of the focus groups were to 1) identify attributes of treatment that RA patients prefer or prioritize as most important in their treatment decisions, and 2) elicit recommendations for, and assess the utility of, a web tool to facilitate decision-making about RA treatment. Findings outlined in the IVI report are based on focus groups conducted in January 2017 with RA patients residing in the Atlanta, Georgia metropolitan area.